AbbVie/J&J Withdrawal Of Imbruvica Indications Clears Space For Competitors

The BTK inhibitor’s exit from MCL and MZL after lackluster Phase III confirmatory trial results gives AstraZeneca’s Calquence and BeiGene’s Brukinsa a potential shot at claiming the space.